Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, Demarles D, Gillotin C, Bidault R, Taburet AM. Goujard C, et al. Among authors: bollens d. Antimicrob Agents Chemother. 2003 Jan;47(1):118-23. doi: 10.1128/AAC.47.1.118-123.2003. Antimicrob Agents Chemother. 2003. PMID: 12499178 Free PMC article. Clinical Trial.
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.
Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard PM, Bélarbi L, Guérin C, Dimet J, Williams V, Krivine A, Salmon D, Lortholary O, Rey D; HEPAVAC Study Group1. Launay O, et al. J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):272-5. doi: 10.1097/QAI.0b013e318183a9c0. J Acquir Immune Defic Syndr. 2008. PMID: 18845961 Clinical Trial.
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.
68 results